Compare KRNT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | DRUG |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.7M | 778.4M |
| IPO Year | 2014 | 2020 |
| Metric | KRNT | DRUG |
|---|---|---|
| Price | $16.80 | $22.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $25.00 | ★ $123.23 |
| AVG Volume (30 Days) | ★ 315.0K | 251.2K |
| Earning Date | 11-18-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.48 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $18.10 |
| 52 Week High | $19.78 | $123.75 |
| Indicator | KRNT | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 26.49 |
| Support Level | $14.56 | N/A |
| Resistance Level | $16.80 | $58.93 |
| Average True Range (ATR) | 0.68 | 4.28 |
| MACD | -0.19 | -3.30 |
| Stochastic Oscillator | 30.20 | 13.87 |
Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.